Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors

被引:5
|
作者
Mendonca, Nikolai P. [1 ]
Kadayakkara, Deepak K. [1 ]
Forde, Inga C. [1 ]
Rudkovaskaia, Anastasiia [1 ]
Saul, Zane K. [1 ]
Lobo, David J. [1 ]
机构
[1] Bridgeport Hosp, Yale New Haven Hlth, Dept Internal Med, Bridgeport, CT USA
来源
关键词
Lymphopenia; Multiple Myeloma; Nocardia; Proteasome Inhibitors;
D O I
10.12659/AJCR.896280
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Rare co-existance of disease or pathology Background: The use of proteasome inhibitors like Bortezomib to treat multiple myeloma has been associated with increased rates of opportunistic infections, including Nocardia, especially when lymphopenia is present. The prevalence or association of such infections with newer agents like Carfilzomib is not known. Case Report: A 71-year-old man with multiple myeloma presented with a 6-week history of respiratory symptoms and cyclic fevers. He was undergoing chemotherapy with Carfilzomib. Work-up revealed severe lymphopenia and a CT chest showed multiple lung nodules and a mass-like consolidation. He underwent a bronchoscopy, and respiratory cultures grew Nocardia species. He responded well to intravenous antibiotics with resolution of symptoms and CT findings. Conclusions: With the introduction of newer agents like Carfilzomib for the treatment of multiple myeloma, clinicians must maintain a high degree of suspicion for opportunistic infections to achieve early diagnosis and treatment.
引用
收藏
页码:76 / 78
页数:3
相关论文
共 50 条
  • [21] The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors
    Alkharabsheh, Omar
    Sidiqi, M. Hasib
    Aljama, Mohammed A.
    Gertz, Morie A.
    Frankel, Arthur E.
    ACTA HAEMATOLOGICA, 2020, 143 (02) : 118 - 123
  • [22] Sequencing of Proteasome Inhibitors in Patients with Multiple Myeloma
    Diamond, Benjamin
    Rossi, Adriana C.
    Pearse, Roger N.
    Jayabalan, David
    Perry, Arthur
    Pekle, Karen
    Mark, Tomer
    Niesvizky, Ruben
    BLOOD, 2016, 128 (22)
  • [23] Proteasome Inhibitors and Modulators of Angiogenesis in Multiple Myeloma
    Ferrarini, M.
    Ferrero, E.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (34) : 5185 - 5195
  • [24] Safety of proteasome inhibitors for treatment of multiple myeloma
    Schlafer, Danielle
    Shah, Katherine S.
    Panjic, Elyse Hall
    Lonial, Sagar
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (02) : 167 - 183
  • [25] CARDIAC STRUCTURE AND FUNCTION IN PATIENTS TREATED WITH PROTEASOME INHIBITORS FOR RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
    Dahm, Cherie
    Mallugari, Ravinder
    Ky, Bonnie
    Cornell, Robert
    Lenihan, Daniel
    Gupta, Deepak K.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 1085 - 1085
  • [26] Recovery from acute kidney injury treated with dialysis in patients with multiple myeloma treated with proteasome inhibitors
    Kanduri, Swetha R.
    Badari, Ambuga
    Ullah, Farhan
    Yang, Chien-Wen
    Velez, Juan Carlos Q.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2025,
  • [27] Use of proteasome inhibitors in the treatment of patients with multiple myeloma
    Rukavitsyn, O. A.
    TERAPEVTICHESKII ARKHIV, 2006, 78 (10) : 40 - 44
  • [28] Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma
    Cole, Daniel C.
    Frishman, William H.
    CARDIOLOGY IN REVIEW, 2018, 26 (03) : 122 - 129
  • [29] The effects of proteasome inhibitors on bone remodeling in multiple myeloma
    Zangari, Maurizio
    Suva, Larry J.
    BONE, 2016, 86 : 131 - 138
  • [30] Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma
    Leleu, Xavier
    Martin, Thomas G.
    Einsele, Hermann
    Lyons, Roger M.
    Durie, Brian G. M.
    Iskander, Karim S.
    Ailawadhi, Sikander
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (01): : 9 - 22